Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/10/2025 | $410.00 | Neutral → Buy | Citigroup |
| 9/10/2025 | $368.00 | Neutral → Buy | BofA Securities |
| 9/10/2025 | $275.00 → $345.00 | Outperform | BMO Capital Markets |
| 9/9/2025 | $245.00 → $275.00 | Outperform | BMO Capital Markets |
| 7/17/2025 | $300.00 | Sector Outperform | Scotiabank |
| 7/10/2025 | $270.00 | Neutral → Overweight | Piper Sandler |
| 7/2/2025 | $235.00 → $245.00 | Outperform | BMO Capital Markets |
| 6/30/2025 | $250.00 | Hold → Buy | Stifel |
4 - ORACLE CORP (0001341439) (Issuer)
4 - ORACLE CORP (0001341439) (Issuer)
4 - ORACLE CORP (0001341439) (Issuer)
Collaboration to enable healthcare professionals to access and interpret genomic data alongside patient medical history Oracle Health and Life Sciences Summit — DNAnexus, Inc., global provider of the leading enterprise platform for precision health data, today announced its intention to bring precision medicine capabilities to select Oracle Health clinical applications. Incorporating genomic data into the clinical setting will help power a new wave of medical advances that can support better treatment plans. By combining DNAnexus' advanced genomics data infrastructure with Oracle Health EHR, the companies can redefine the future of precision medicine and provide clinicians with the tool
New AI-powered capabilities within Oracle Fusion Cloud Applications help healthcare organizations improve visibility, boost efficiency, reduce costs, and support patient care ORLANDO, Fla., Sept. 11, 2025 /PRNewswire/ -- Oracle Health & Life Sciences Summit -- Oracle today announced new AI-powered capabilities within Oracle Fusion Cloud Applications that help healthcare organizations strengthen and streamline supply chain operations. Building on Oracle's decades of success in helping healthcare organizations increase efficiency, the new inventory management and procurement capabilities help supply chain professionals leverage AI to better support patient care by simplifying healthcare proces
AUSTIN, Texas and VANCOUVER, Washington, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Absci, a clinical-stage biotech company advancing novel therapeutics with generative AI, today announced a collaboration with Oracle Cloud Infrastructure (OCI) and AMD to accelerate generative AI-driven drug discovery. Absci's generative AI Drug Creation Platform leverages OCI's AI infrastructure and AMD's latest hardware, enabling it to consolidate its infrastructure and accelerate its biologics design cycles. To advance Absci's mission of creating better biologics for patients more quickly, Absci has selected OCI as the technical foundation for developing AI models and scaling AI workflows. With OCI, Absci h
10-Q - ORACLE CORP (0001341439) (Filer)
8-K - ORACLE CORP (0001341439) (Filer)
144 - ORACLE CORP (0001341439) (Subject)
Citigroup upgraded Oracle from Neutral to Buy and set a new price target of $410.00
BofA Securities upgraded Oracle from Neutral to Buy and set a new price target of $368.00
BMO Capital Markets reiterated coverage of Oracle with a rating of Outperform and set a new price target of $345.00 from $275.00 previously
4 - ORACLE CORP (0001341439) (Issuer)
4 - ORACLE CORP (0001341439) (Issuer)
4 - ORACLE CORP (0001341439) (Issuer)
SoftBank Group Corp. (TSE: 9984, "SoftBank Group") today announced that it will acquire Ampere® Computing, a leading independent silicon design company, in an all-cash transaction valued at $6.5 billion. Under the terms of the agreement, Ampere will operate as a wholly owned subsidiary of SoftBank Group and retain its name. As part of the transaction, Ampere's lead investors – Carlyle (NASDAQ:CG) and Oracle Corp. (NYSE:ORCL) – are selling their respective positions in Ampere. As SoftBank Group broadens its AI infrastructure investments in ventures such as Cristal intelligence and Stargate, the acquisition will help enhance SoftBank Group's capabilities in key areas and accelerate its growt
Life sciences, academic medical centers, health systems, and research institutes can gain insights into diseases and their impact on patients to optimize therapeutic launch strategies Pre-built and continuously updated analytics platform has unprecedented variety of real-world data sources, including CancerMPact and multiomics NASHVILLE, Tenn., Oct. 30, 2024 /PRNewswire/ -- Oracle Health Summit -- Oracle today launched Oracle Analytics Intelligence for Life Sciences. The AI-powered, cloud-scale, data and analytics platform streamlines and helps accelerate insight generation by unifying disparate data sets into a single, intelligent workbench. The new solution empowers users to answer multidi
Oracle is collaborating with Meharry Medical College regarding technology and resources for students and providers, a research collaborative, and a Meharry established community clinic and wellness center NASHVILLE, Tenn., Oct. 30, 2024 /PRNewswire/ -- Oracle Health Summit -- Oracle Health and Meharry Medical College today announced plans to improve medical education and community healthcare across Middle Tennessee and beyond. As part of their non-binding MOU, Meharry and Oracle aim to establish a health technology education and research collaborative, a health innovation hub, and a community care and wellness center in Nashville. The two organizations will also work together to cultivate th
Q1 Remaining Performance Obligations $455 billion, up 359% in both USD and constant currencyQ1 GAAP Earnings per Share down 2% to $1.01, Non-GAAP Earnings per Share up 6% to $1.47Q1 Total Revenue $14.9 billion, up 12% in USD and up 11% in constant currencyQ1 Cloud Revenue (IaaS plus SaaS) $7.2 billion, up 28% in USD and up 27% in constant currency Q1 Cloud Infrastructure (IaaS) Revenue $3.3 billion, up 55% in USD and up 54% in constant currency Q1 Cloud Application (SaaS) Revenue $3.8 billion, up 11% in USD and up 10% in constant currencyQ1 Fusion Cloud ERP (SaaS) Revenue $1.0 billion, up 17% in USD and up 16% in constant currencyQ1 NetSuite Cloud ERP (SaaS) Revenue $1.0 billion, up 16% in U
Earnings Results to be released on September 9, 2025, After the Close of the Market AUSTIN, Texas, Sept. 2, 2025 /PRNewswire/ -- Oracle Corporation today announced that its first quarter fiscal year 2026 results will be released on Tuesday, September 9th, after the close of the market. Oracle will host a conference call and live webcast at 4:00 p.m. Central Time to discuss the financial results. The live webcast will be available on the Oracle Investor Relations website at www.oracle.com/investor. About OracleOracle offers integrated suites of applications plus secure, auton
Q4 Remaining Performance Obligations up 41% to $138 billionQ4 GAAP Earnings per Share $1.19, non-GAAP Earnings per Share $1.70Q4 Total Revenue $15.9 billion, up 11%Q4 Cloud Revenue (IaaS plus SaaS) $6.7 billion, up 27%Q4 Cloud Infrastructure (IaaS) Revenue $3.0 billion, up 52%Q4 Cloud Application (SaaS) Revenue $3.7 billion, up 12%Q4 Fusion Cloud ERP (SaaS) Revenue $1.0 billion, up 22%Q4 NetSuite Cloud ERP (SaaS) Revenue $1.0 billion, up 18%FY 2025 Total Revenue $57.4 billion, up 8%AUSTIN, Texas, June 11, 2025 /PRNewswire/ -- Oracle Corporation (NYSE:ORCL) today announced fiscal 2025 Q4 and full-year 2025 results. Total quarterly revenues were up 11% year-over-year in USD and constant curren
SC 13G/A - ORACLE CORP (0001341439) (Subject)
SC 13G/A - ORACLE CORP (0001341439) (Subject)
SC 13G/A - ORACLE CORP (0001341439) (Subject)